论文部分内容阅读
目的 探讨高压氧（ＨＢＯ）对晚期中、高度恶性非何杰金淋巴瘤（ＮＨＬ）远期疗效的影响。方法 采用随机分组对照、自身对照和长期随访方法，分析比较ＨＢＯ与ＡＢＣＯＤ方案联合治疗（ＨＢＯ组４６ 例）和单纯ＡＢＣＯＤ方案化疗（对照组３２ 例）对晚期中、高度恶性ＮＨＬ的疗效。观察指标包括瘤块消退速度、诱导缓解（ＣＲ）时间、ＣＲ率、ＣＲ持续时间以及３ 年和５ 年无病生存率。结果 ＨＢＯ组的ＣＲ率为８９．５％ ，３年生存率为５５．３％ ，３ 年无病生存率为５０．０％ ，５ 年无病生存率为３９．５％ ；而对照组分别为５０．０％ ，２３．３％ ，１６．７％ 和１６．７％ 。ＨＢＯ组中位ＣＲ持续时间为４５ 个月，中位生存期为４７ 个月；对照组分别为２５个月和２６个月。上述两组各项指标差异均有显著性意义。结论 ＨＢＯ 能明显提高晚期中、高度恶性ＮＨＬ的化疗远期疗效。ＨＢＯ与化疗联合治疗该病有协同作用且医疗费用较低和毒副作用少，值得推广应用
Objective To investigate the effect of hyperbaric oxygenation (HBO) on the long-term efficacy of advanced-stage, high-grade malignant non-Hodgkin’s lymphoma (NHL). METHODS Randomized controlled group, self-control and long-term follow-up were used to analyze the efficacy of combination of HBO and ABCOD regimen (46 cases in HBO group) and simple ABCOD regimen (32 cases in control group) in the treatment of advanced stage and high grade NHL. Observations included tumor regression rate, induced remission (CR) time, CR rate, CR duration, and 3- and 5-year disease-free survival. Results The CR rate in HBO group was 89.5%, the 3-year survival rate was 55.3%, the 3-year disease-free survival rate was 50.0%, the 5-year disease-free survival rate was 39.5%, and the control group It is 50.0%, 23.3%, 16.7% and 16.7%. The median duration of CR in the HBO group was 45 months, with a median survival of 47 months; the control group was 25 months and 26 months, respectively. The above two sets of indicators have significant differences. Conclusion HBO can significantly improve the long-term efficacy of chemotherapy for advanced and moderately advanced NHL. The combination therapy of HBO and chemotherapy has a synergistic effect, lower medical costs and fewer toxic and side effects, and is worthy of promotion and application.